"Designing Growth Strategies is in our DNA"

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor Inhibitors, Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, and Others), By Route of Administration (Oral and Parenteral), By Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Immunotherapy), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: November 17, 2025 | Format: PDF | Report ID: FBI112690

 


Metastatic Castration-Resistant Prostate Cancer Therapeutics Market
  • 2019-2032
  • 2024
  • 2019-2023
  • 278
Download Free Sample

    man icon
    Mail icon
Growth Advisory Services
    How can we help you uncover new opportunities and scale faster?
Clients
3M
Toshiba
Fresenius
Johnson
Siemens
Abbot
Allergan
American Medical Association
Becton, Dickinson and Company
Bristol-Myers Squibb Company
Henry Schein
Mckesson
Mindray
National Institutes of Health (NIH)
Nihon Kohden
Olympus
Quest Diagnostics
Sanofi
Smith & Nephew
Straumann